Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2019
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2017
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Samus Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2017
Lead Product(s) : SUPVGFZUWFMATN-UHFFFAOYSA-N
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Samus Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable